ArticleReproductive sciences (Thousand Oaks, Calif.)2025
Beneficial Effects of Alchemilla vulgaris in DHEA-Induced Rat Model of Polycystic Ovary Syndrome.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alchemilla Vulgaris Compounds as Inhibitors of HPV 16 E6 Oncoprotein: Quercetin with Promising in Silico Potential.Materia socio-medica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alchemilla vulgaris has traditionally been used to treat gynecologic diseases. The anti-inflammatory and vasorelaxant effects of the extract of A. vulgaris (AVE) have been reported in previous studies. This study aimed to investigate the effects of A. vulgaris on PCOS, one of the most common metabolic disorders in adult women of reproductive age, accompanied by inflammation and vascular endothelial dysfunction, in an experimental animal model. Three groups of prepubertal female Wistar rats were established: PCOS, Control, and PCOS + AVE groups. Subcutaneous dehydroepiandrosterone (DHEA) was administered for 35 days to the PCOS and PCOS + AVE groups. The rats in the PCOS + AVE group were orally administered AVE (50 mg/100 g bw/day) for 35 days. Systemic blood pressure, vascular endothelial function, ovarian morphology, and endocrine biomarker levels were measured at the end of the experiment. TNF-α levels were also evaluated in the thoracic aorta and ovaries. Hormonal imbalances, ovarian morphological changes, and endothelial dysfunction were observed in the PCOS group, which returned to the controls after AVE treatment. Furthermore, AVE attenuated the aortic and ovarian levels of TNF-α in the PCOS group. Our study suggests that AVE may have beneficial effects in the treatment of PCOS due to its anti-inflammatory and vasculoprotective properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.